Jim Cramer Says He “Believed in” Bristol-Myers’ Cobenfy But “It’s Not Selling Well at All”

Core Insights - Bristol-Myers Squibb Company (NYSE:BMY) is facing challenges with its schizophrenia medicine sales, leading to disappointment from investors [1] - The company develops biopharmaceutical products targeting cancer, cardiovascular, autoimmune, and neurological diseases [1] - Comparatively, Johnson & Johnson (J&J) is perceived to be performing better than Bristol-Myers Squibb, causing concern among investors [1] - There is a belief that certain AI stocks may present better investment opportunities with higher upside potential and lower downside risk compared to Bristol-Myers Squibb [1] Company Performance - Jim Cramer expressed doubts about the sales performance of Bristol-Myers Squibb's schizophrenia medication, Cobenfy, indicating it is not selling well [1] - Cramer mentioned that he has not added to his position in Bristol-Myers Squibb due to concerns about its performance relative to competitors like J&J [1] Investment Perspective - While acknowledging the potential of Bristol-Myers Squibb as an investment, there is a suggestion that investors may find more value in certain AI stocks [1]